LAG-3 Antagonist Combination Therapy for Limited NSCLC Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung cancer, particularly non-small cell lung cancer (NSCLC), have limited efficacy, with median survival rates of approximately 10-22 months despite advancements in immune checkpoint inhibitors, highlighting the need for improved therapeutic methods.
Innovation Solution
Administering a lymphocyte activation gene-3 (LAG-3) antagonist in combination with platinum doublet chemotherapy (PDCT) as a first, second, or third-line therapy, or for patients who have progressed on prior therapies, including those with unresectable, advanced, recurrent, or metastatic lung cancer, and using specific anti-LAG-3 antibodies or soluble LAG-3 polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors targeting PD-1 signaling pathway are used, then patient survival is improved, but median survival remains limited to approximately 22 months in non-squamous and 15.9 months in squamous population
Solution Approach 1:
The patent combines LAG-3 antagonist with PD-1 pathway inhibitor in a dual immunotherapy regimen, targeting two different immune checkpoint pathways simultaneously. This combination approach merges the mechanisms of action of two distinct immunotherapies to achieve synergistic anti-tumor effects and improve upon the limited survival duration achieved with single-agent PD-1 inhibition alone
Solution Approach 2:
The treatment regimen uses a composite therapeutic approach combining two different immunotherapy agents (LAG-3 antagonist and PD-1 pathway inhibitor) with potentially different molecular structures and mechanisms, creating a composite immunotherapy strategy that leverages the strengths of both agents to overcome the durability limitations of monotherapy
2Reliability
If platinum doublet chemotherapy is used as standard treatment, then treatment efficacy is achieved, but median survival is only approximately 10 months
Solution Approach 1:
The patent merges conventional platinum doublet chemotherapy with LAG-3 antagonist immunotherapy, combining the immediate cytotoxic effects of chemotherapy with the sustained immune-mediated anti-tumor responses of immunotherapy. This combination aims to achieve both short-term tumor control and long-term survival benefit, overcoming the 10-month median survival limitation of chemotherapy alone
Solution Approach 2:
The LAG-3 antagonist acts as an intermediary that bridges conventional chemotherapy and durable immunotherapy responses. By blocking the LAG-3 checkpoint, it enhances T-cell activation and persistence, thereby mediating a transition from transient chemotherapy effects to sustained immune-mediated tumor control and improved long-term survival
Data Source
AI summary
The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and/or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy).